ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ইস্রায়েল - হিব্রু - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe 10 mg; simvastatin 10 mg - tablets - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - simvastatin 20 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - ezetimibe 10 mg; simvastatin 20 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - simvastatin 40 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - ezetimibe 10 mg; simvastatin 40 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - simvastatin 80 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).